Navigation Links
FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
Date:2/25/2011

DEERFIELD, Ill. and OSAKA, Japan, Feb. 25, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved EDARBI (azilsartan medoxomil) for the treatment of hypertension, or high blood pressure, in adults. EDARBI is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone that constricts blood vessels. When the angiotensin II receptor is blocked, blood vessels stay relaxed and open and blood pressure can be reduced. EDARBI is approved as a once-daily oral therapy for use alone and for use in combination with other antihypertensive medications.

Takeda Global Research & Development Center, Inc. U.S. submitted a new drug application (NDA) for EDARBI in April 2010. The NDA was supported by seven controlled phase 3 clinical trials involving more than 5,900 patients with hypertension. Pivotal phase 3 studies showed EDARBI (80 mg/day) was statistically superior to placebo and the highest approved doses of two commonly prescribed ARBs, olmesartan medoxomil (40 mg/day) and valsartan (320 mg/day), in lowering both clinic and 24-hour mean blood pressure measurements.

"We are pleased to be able to build upon our global expertise in the cardiovascular therapeutic area with the approval of EDARBI in the U.S.," said Shinji Honda, president and CEO, Takeda Pharmaceuticals North America. "Through the discovery, development and commercialization of new medicines, Takeda is committed to bringing therapies like EDARBI to market. EDARBI is an important new treatment option for patients with hypertension and the health care professionals who treat them."

The safety and efficacy of EDARBI were studied as a once-daily oral therapy, as well as in combination with chlorthalidone and amlodipine. Results from the phase 3 clinical trials sh
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
2. FDA Approves First 3-D Mammography Imaging System
3. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
4. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
5. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
6. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
7. FDA Approves Viibryd to Treat Major Depressive Disorder
8. FDA Approves Head Lice Treatment for Children and Adults
9. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
10. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
11. FDA Approves New Dosage Strength for INTELENCE®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Ameritox SM , the ... Deadly Trend: Prescription Drugs to Heroin," a research report ... heroin abuse, and examines deadly trends that have created ... here . The report is ... patients prescribed opioids. It examines five trends that distinguish ...
(Date:9/2/2014)... , September 2, 2014 ... by Transparency Market Research "Latin America Home Healthcare ... Therapeutic Home Healthcare Devices, Mobility Assist Devices and ... Respiratory Therapy, Infusion Therapy and Unskilled Home Healthcare ... and Forecast, 2014 - 2020" the Latin American ...
(Date:9/2/2014)... Sept. 2, 2014   Santa Clara dentist , ... special promotion for Invisalign. Invisalign is an orthodontic system ... It is often the orthodontic treatment of choice for ... aesthetics of it. For a limited time, patients can ... savings from the usual cost. This offer cannot be ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... Oct. 29 , AT A GLANCE , ... PEM significantly improves ability to differentiate between benign ... MRI dramatically increased number of suspicious lesions found. ... women diagnosed with breast cancer found that Positron Emission ...
... Hospira, Inc. (NYSE: HSP ) celebrates the 25th anniversary ... 1984, Hospira,s PCA was the first pump of its kind, ... best when they are in pain, so allow them, within ... PCA technology has improved the safety and quality of care ...
Cached Medicine Technology:High-Resolution Breast PET Improves Breast Cancer Detection 2High-Resolution Breast PET Improves Breast Cancer Detection 3Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 2Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 3Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 4
(Date:9/2/2014)... York (PRWEB) September 02, 2014 - ... defined as a class of diagnostic test that analyzes ... The nucleic acids and proteins that belong to individual ... therapy, health condition, or risk of developing a specific ... better known as (MDx) evaluating the new class of ...
(Date:9/2/2014)... 02, 2014 The new Eco-Pro ... reduce discomfort and fatigue by absorbing stress and impact ... renewable bio-foam core, these anti-fatigue mats are intended for ... to a study by the Texas A&M University, Eco-Pro ... in reducing spinal compression and increase in sit-reach flexibility ...
(Date:9/2/2014)... 2014 A New York City based ... a simple, yet revolutionary, product that will ... reducing health care costs for Americans. , ... that puts control in the user's hands. It's a ... the next date of intake by simply turning a ...
(Date:9/2/2014)... September 02, 2014 Welcome to ... over 4.6 million Canadians living with the disease, The ... of Arthritis” video series featuring well-known Canadians from different ... ,      Lloyd Robertson , veteran news anchor ... medal skier ,      Amy Cotton , ...
(Date:9/2/2014)... Ga. A little white pill may help scientists ... capacity than their peers, even if their lungs are ... sildenafil marketed as Revatio to treat pulmonary hypertension ... a cocktail of over-the-counter antioxidants will help them identify ... exercise difficult for these patients. , "We want ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4
... Opus Healthcare Solutions, Inc., a ... today that OpusMobility(R) runs on ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20080325/LATU040LOGO ) Opus ... or Wi-Fi connections on all smart phone devices ...
... January 13, 2009 A benchmarking study ... evaluated contemporary hospital glycemic management in United ... are suboptimal and do not meet current American ... The retrospective cohort study was based upon a ...
... its annual Molecular Imaging Summit to introducing the new ... Hilton Clearwater Hotel, Clearwater, Fl. In part, the program ... Network, which was designed to facilitate cost-effective drug development ... 2, 3 and 4 therapeutics clinical trials. In addition, ...
... health care policyWASHINGTON, Jan. 13 The RAND ... policymakers and interested parties with a unique way ... consequences of health care reform proposals certain to ... beyond. COMPARE (Comprehensive Assessment of Reform Efforts) is ...
... ATLANTA, Jan. 13 Vendormate nearly tripled its customer,base ... in 42 states across the,U.S. in part because of ... help mitigate the risk of supply chain,interruptions. , ... and financial service,providers in particular are anxious about their ...
... Family,Services, Inc. No. 2851 on its annual ranking of ... marks the second consecutive year that,Access Family Services has ... the most,comprehensive look at the most important segment of ... whole, these companies represent,the backbone of the U.S. economy. ...
Cached Medicine News:Health News:OpusMobility(R) Clinical Information System Runs on Google G1 Smart Phone 2Health News:OpusMobility(R) Clinical Information System Runs on Google G1 Smart Phone 3Health News:Annual SNM MI summit introduces the clinical trials network 2Health News:RAND Launches Unique Tool to Evaluate Health Care Proposals 2Health News:RAND Launches Unique Tool to Evaluate Health Care Proposals 3Health News:RAND Launches Unique Tool to Evaluate Health Care Proposals 4Health News:Economic Uncertainty Fuels Vendormate Growth in 2008 2Health News:Access Family Services, Inc. Makes the List for the Second Year in a Row! Access Family Services 2008 Ranks No. 2851 on the Inc. 5000 With Three-Year Sales Growth of 128% 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: